AI search makes message measurement a healthcare priority

Tern plc

Clicks are no longer enough to show whether healthcare messages are reaching and influencing the right audience.

As generative AI becomes part of everyday search, more people are getting answers directly from AI tools rather than visiting websites.

This changes how digital visibility needs to be assessed. Traditional search measurement has focused on rankings, traffic and conversions. These remain useful, but they do not show how AI tools are summarising a company, medicine or health topic. In the generative engine optimisation era, the key issue is what is being said about it.

In healthcare, that distinction is important. Messages need to be accurate, consistent and aligned with the way a company wants its products or expertise to be understood. If an AI-generated answer leaves out a key message, uses unclear language or places a competitor in a stronger context, that can affect positioning even when no website visit takes place.

Message measurement gives companies a way to track this new layer of influence. It looks at how often important messages appear, how they are framed, which sources are shaping AI-generated answers and how brands compare within those answers. This helps decision-makers see where messaging is strong, where it may be at risk and where content needs to be improved.

Optimising for AI search is about being represented correctly. As healthcare professionals, patients and consumers use AI tools to understand health topics, the quality of the answer becomes a commercial and reputational issue.

Talking Medicines highlights this shift as a move beyond clicks towards a more complete view of message impact. Website analytics can show whether someone arrived at a page. Message measurement can show whether the intended narrative is being carried through AI-led discovery.

AI search is changing how information is found, how brands are compared and how trust is formed. Companies that understand how their messages appear in these environments will be better placed to manage risk, strengthen positioning and respond faster as discovery behaviour changes.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Search